Display options
Cite
Bayani M, Siadati S, Rajabnia R, et al. Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran. Int J Mol Cell Med. 2013;2(4):204-9
Bayani, M., Siadati, S., Rajabnia, R., & Taher, A. A. (2013). Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran. International journal of molecular and cellular medicine, 2(4), 204-9.
Bayani, Masoomeh, et al. "Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran." International journal of molecular and cellular medicine vol. 2,4 (2013): 204-9.
Bayani M, Siadati S, Rajabnia R, Taher AA. Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran. Int J Mol Cell Med. 2013;2(4):204-9. PMID: 24551814; PMCID: PMC3927384.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Cell Med. 2013;2(4):204-9.

Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran.

International journal of molecular and cellular medicine

Masoomeh Bayani, Sepideh Siadati, Ramzan Rajabnia, Ali Asghar Taher

Affiliations

  1. Infectious Disease and Tropical Research Center, Babol University of Medical Sciences, Babol, Iran.
  2. Department of Pathology, Babol University of Medical Sciences, Babol, Iran.

PMID: 24551814 PMCID: PMC3927384

Abstract

Multidrug resistant (MDR) bacteria are spread throughout the world which causes nosocomial infections, especially in Intensive Care Unit (ICU). This study aimed to investigate the resistance pattern of Pseudomonas aeruginosa and Enterobacter cloacae isolated from patients in the ICU. During 2011-2012, 30 isolates for each P. aeruginosa and E. cloacae were collected from the patients who acquired nosocomial infection after admition to the ICU at the hospitals affiliated to Babol University of Medical Sciences, Babol, northern Iran. Antimicrobial susceptibility test was performed for five category antibiotics by microdilution method. The data were analyzed by SPSS version 20 and p<0.05 was considered statistically significant. The highest resistance rate of P. aeruginosa was seen to amikacin (53.3%) followed by ceftazidime (43.3%). Also, 16.7% of E. cloacae was resistant to ceftazidime. Among P. aeruginosa isolates,18 (60%) were MDR while no E. cloacae isolates were MDR. The significant correlation was only demonstrated between MDR P. aeruginosa and the reason of hospitalization (P=0.004). In conclusion, there was alarming amount of P. aeruginosa MDR in patients in the ICU which could lead to a hazardous outcome for the patients. Therefore, new prevention policies regarding to hospital infection should be established. Also, the periodical assessment of bacterial resistance pattern particularly in ICUs should be performed.

Keywords: E cloacae; Intensive care unit; P aeruginos; nosocomial infections

References

  1. Ann Clin Microbiol Antimicrob. 2003 Mar 07;2:5 - PubMed
  2. J Antimicrob Chemother. 1999 Mar;43(3):373-8 - PubMed
  3. Indian J Crit Care Med. 2009 Jul-Sep;13(3):148-51 - PubMed
  4. Indian J Med Res. 2008 Jan;127(1):85-8 - PubMed
  5. Clin Microbiol Infect. 2012 Mar;18(3):268-81 - PubMed
  6. Int J Mol Cell Med. 2012 Fall;1(4):209-17 - PubMed
  7. Braz J Infect Dis. 2009 Apr;13(2):118-22 - PubMed
  8. Curr Opin Crit Care. 2003 Oct;9(5):413-23 - PubMed
  9. Crit Care Med. 2011 Nov;39(11):2458-63 - PubMed
  10. Clin Microbiol Infect. 2010 Jul;16(7):902-8 - PubMed
  11. Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):403-7 - PubMed
  12. Iran J Microbiol. 2013 Mar;5(1):36-41 - PubMed
  13. J Chemother. 2006 Dec;18(6):589-602 - PubMed
  14. J Clin Microbiol. 2007 Oct;45(10):3352-9 - PubMed
  15. Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2791-7 - PubMed
  16. Jpn J Infect Dis. 2005 Aug;58(4):228-31 - PubMed
  17. Glob J Health Sci. 2012 Nov 11;5(1):143-9 - PubMed
  18. Diagn Microbiol Infect Dis. 2006 Sep;56(1):57-62 - PubMed
  19. Caspian J Intern Med. 2013 Spring;4(2):654-7 - PubMed
  20. Clin Microbiol Infect. 1997 Apr;3(2):208-215 - PubMed
  21. J Infect. 2012 Mar;64(3):299-310 - PubMed
  22. Int J Antimicrob Agents. 2010 Nov;36(5):408-14 - PubMed
  23. Antimicrob Agents Chemother. 2009 Aug;53(8):3280-4 - PubMed

Publication Types